Show simple item record

dc.contributor.authorFehér, Csaba
dc.contributor.authorPastor-Ibáñez, Roque
dc.contributor.authorLeal, Lorna
dc.contributor.authorPlana, Montserrat
dc.contributor.authorArnedo, Mireia
dc.contributor.authorvan den Ham, Henk-Jan
dc.contributor.authorAndeweg, Arno C
dc.contributor.authorGruters, Rob A
dc.contributor.authorDíez-Fuertes, Francisco 
dc.contributor.authorAlcamí, José 
dc.contributor.authorAloy, Patrick
dc.contributor.authorGarcía, Felipe
dc.date.accessioned2022-04-22T15:47:49Z
dc.date.available2022-04-22T15:47:49Z
dc.date.issued2021-07-19
dc.identifier.citationVaccines (Basel). 2021;9(7):799.es_ES
dc.identifier.issn2076-393Xes_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/14160
dc.description.abstractSystems vaccinology has seldomly been used in therapeutic HIV-1 vaccine research. Our aim was to identify early gene 'signatures' that predicted virus load control after analytical therapy interruption (ATI) in participants of a dendritic cell-based HIV-1 vaccine trial (DCV2). mRNA and miRNA were extracted from frozen post-vaccination PBMC samples; gene expression was determined by microarray method. In gene set enrichment analysis, responders showed an up-regulation of 14 gene sets (TNF-alpha/NFkB pathway, inflammatory response, the complement system, Il6 and Il2 JAK-STAT signaling, among others) and a down-regulation of 7 gene sets (such as E2F targets or interferon alpha response). The expression of genes regulated by three (miR-223-3p, miR-1183 and miR-8063) of the 9 differentially expressed miRNAs was significantly down-regulated in responders. The deregulation of certain gene sets related to inflammatory processes seems fundamental for viral control, and certain miRNAs may be important in fine-tuning these processes.es_ES
dc.description.sponsorshipThis study was supported by the European Commission (grants: H2020-SC1-2016-RTD Proposal: 731626), the Spanish Ministry of Economy (MINECO) (grants: SAF2015-66193-R, RTI2018-096309-B-I00), the Fondo de Investigación Sanitaria (FIS) PI15/00480, AC16/00051, and PI18/00699, amfAR Grant # 108821-55-RGRL, the Fondo Europeo para el Desarrollo Regional (FEDER), the SPANISH AIDS Research Network RD16/0025/0002–ISCIII–FEDER (RIS), and the CERCA Program/Generalitat de Catalunya SGR 615. F.G. has received the support of José María Segovia de Arana contracts. C.F. held a fellowship from “PhD4MD,” a Collaborative Research Training Programme for Medical Doctors financed by IRB Barcelona (Institute for Research in Biomedicine) and IDIBAPS (August Pi i Sunyer Biomedical Research Institute) during the study.es_ES
dc.language.isoenges_ES
dc.publisherMultidisciplinary Digital Publishing Institute (MDPI) es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectDendritic cell-based therapeutic HIV-1 vaccinees_ES
dc.subjectDifferential gene expressiones_ES
dc.subjectGene set enrichment analysises_ES
dc.subjectmiRNAes_ES
dc.subjectmMRAes_ES
dc.titleAssociation of Transcriptomic Signatures of Inflammatory Response with Viral Control after Dendritic Cell-Based Therapeutic Vaccination in HIV-1 Infected Individualses_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID34358215es_ES
dc.format.volume9es_ES
dc.format.number7es_ES
dc.format.page799es_ES
dc.identifier.doi10.3390/vaccines9070799es_ES
dc.contributor.funderGovernment of Catalonia (España) es_ES
dc.contributor.funderRed de Investigación Cooperativa en Investigación en Sida (España) es_ES
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) es_ES
dc.contributor.funderMinisterio de Economía (España) es_ES
dc.contributor.funderInstituto de Salud Carlos III es_ES
dc.contributor.funderUnión Europea. Comisión Europea es_ES
dc.description.peerreviewedes_ES
dc.relation.publisherversionhttps://doi.org/10.3390/vaccines9070799es_ES
dc.identifier.journalVaccineses_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/H2020/731626/EUes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/108821-55-RGRLes_ES
dc.rights.accessRightsopen accesses_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/MINECO//SAF2015-66193-R/ES/UTILIZACION DE MEDICINA DE SISTEMAS PARA LA PREDICCION DE LA INMUNOGENICIDAD Y EFICACIA DE VACUNAS TERAPEUTICAS FRENTE A VIH/ es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/RTI2018-096309-B-I00es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/MINECO//RD16%2F0025%2F0002/ES/RED ESPAÑOLA DE INVESTIGACIÓN EN SIDA (RIS)/ es_ES
dc.relation.projectFISinfo:fis/Instituto de Salud Carlos III/null/null/Subprograma de proyectos de investigacion en salud (AES 2015). Modalidad proyectos en salud. (2015)/PI15/00480es_ES
dc.relation.projectFISinfo:fis/Instituto de Salud Carlos III/Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia/Subprograma Estatal de Generación de Conocimiento/PI18 - Proyectos de investigacion en salud (AES 2018). Modalidad proyectos en salud. (2018)/PI18/00699es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/AC16/00051es_ES


Files in this item

Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional